New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Autolus Therapeutics PLC Sponsored ADR (AUTL) vs Prelude Therapeutics Incorporated (PRLD)

Autolus Therapeutics PLC Sponsored ADR and Prelude Therapeutics Incorporated are both Biotechnology companies. Autolus Therapeutics PLC Sponsored ADR and Prelude Therapeutics Incorporated are of similar size ($260.9M and $260.5M). Autolus Therapeutics PLC Sponsored ADR has the higher net margin (−186.4% vs −247.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Prelude Therapeutics Incorporated leads on 11 and Autolus Therapeutics PLC Sponsored ADR on 4.

Valuation

Metric AUTL PRLD Biotechnology median
P/E n/m n/m 8.49
P/S 1.76 15.44 8.56
P/B 8.84 2.68 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA n/m n/m 0.69
EV/Sales 0.99 8.95 8.00
Earnings yield (106.26%) (18.32%) (35.81%)
Free cash flow yield (74.39%) (8.40%) (25.41%)

Profitability

Metric AUTL PRLD Biotechnology median
Gross margin 35.76% 100.00% 70.18%
Operating margin (159.61%) (283.92%) 0.00%
Net margin (186.37%) (247.12%) 0.00%
Free cash flow margin (131.12%) (129.68%) 0.00%
Return on equity (174.92%) (58.36%) (51.58%)
Return on assets (43.23%) (39.45%) (45.91%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AUTL PRLD Biotechnology median
Revenue growth (TTM) 168.80% — 7.20%
EPS growth (last fiscal year) (25.58%) 23.21% 29.04%
Revenue growth, 5-year CAGR 113.11% — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric AUTL PRLD Biotechnology median
Debt to equity 5.25 0.00 0.00
Current ratio 3.72 4.20 4.79
Net debt to EBITDA 1.16 1.00 1.01

Dividend

Metric AUTL PRLD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AUTL PRLD Biotechnology median
Market cap 260.91m 260.48m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack